Phase II Clinical Trial of KJ101in the Treatment of Deep II Degree Burns

Inclusion criteria: 1. Male and female subjects aged 18 to 65 years inclusive, who are neither pregnant nor lactating; 2. Clinically diagnosed with superficial or deep II degree burns within 72 hours of injury, with a total burn area of ≤30% TBSA. The target burn wound must be isolated or have distinguishable boundaries, with an area between 40 and 200 cm². 3. Subjects of childbearing age must agree to use effective and safe contraceptive methods during the treatment period and for three months after the final administration. Exclusion criteria: 1. Individuals who are known to be allergic to any component of the test drug or who have a tendency to allergies. 2. Burns caused by specific factors, such as electrical or chemical burns. 3. Subjects with shock or inhalation lung injury; 4. Subjects with target wounds complicated by inflammatory skin diseases (e.g. atopic dermatitis, eczema or psoriasis), or who have undergone enzymatic debridement (e.g. with collagenase, papain, bromelain, chymotrypsin or trypsin). 5. Subjects who, during screening, are judged by the investigator to have other severe systemic infections requiring systemic treatment; 6. Abnormal liver or kidney function.